Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Natco Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was ₹8.66.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹85.29.
During the past 12 months, the average EBIT per Share Growth Rate of Natco Pharma was -37.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 16.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 46.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Natco Pharma's EBIT per Share or its related term are showing as below:
NSE:NATCOPHARM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -41.7 Med: 17.1 Max: 142.1
Current: 16.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Natco Pharma was 142.10% per year. The lowest was -41.70% per year. And the median was 17.10% per year.
NSE:NATCOPHARM's 3-Year EBIT Growth Rate is ranked better than 64.21% of 813
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NSE:NATCOPHARM: 16.60
Natco Pharma's EBIT for the
three
months ended in Mar. 2026 was ₹1,550 Mil.
Natco Pharma (NSE:NATCOPHARM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Natco Pharma EBIT per Share Related Terms
Natco Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Natco Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹85.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natco Pharma (NSE:NATCOPHARM) has a EBIT per Share of ₹85.29 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Natco Pharma and its competitors. According to the industry distribution chart, Natco Pharma ranks #291 out of 813 companies in the Drug Manufacturers industry, placing it in the top 35.8%.
Is Natco Pharma's EBIT per Share too high?
Natco Pharma's current EBIT per Share is ₹85.29. Based on the distribution chart, Natco Pharma ranks #291 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #291 out of 813 companies for EBIT per Share. This puts Natco Pharma in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current EBIT per Share is ₹85.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹925.83, compared to a current price of ₹929.85 — trading 0.4% above its estimated fair value. The current EBIT per Share is ₹85.29. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current EBIT per Share is ₹85.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued.
The current stock price of ₹929.85 is trading 0.4% above its estimated GF Value™ of ₹925.83.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
EBIT per Share: ₹85.29
GF Value™: ₹925.83 vs. price of ₹929.85 (0.4% above fair value)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score
Get the complete analysis for NSE:NATCOPHARM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
